カテゴリ： Allied Market Research, 世界, 医療/バイオ

非小細胞性肺がんのグローバル市場（2021〜2031）：腺癌、扁平上皮癌、大細胞癌、その他

■ 英語タイトル：Global Non Small-Cell Lung Cancer Market By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB253）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB253
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：262
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[非小細胞性肺がんのグローバル市場（2021〜2031）：腺癌、扁平上皮癌、大細胞癌、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に15,335.0百万ドルであった世界の非小細胞性肺がん市場規模が、2031年までに36,934.19百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）9.3%で成長すると予測しています。本レポートは、非小細胞性肺がんの世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、種類別（腺癌、扁平上皮癌、大細胞癌、その他）分析、治療別（化学治療、標的治療、免疫治療）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、F. Hoffmann-La Roche Ltd、Novartis AG、Pfizer Inc.、Astrazeneca、Eli Lilly and Company、Merck & Co., Inc.、Bristol-Myers Squibb Companyなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の非小細胞性肺がん市場規模：種類別
- 腺癌における市場規模
- 扁平上皮癌における市場規模
- 大細胞癌における市場規模
- その他における市場規模
・世界の非小細胞性肺がん市場規模：治療別
- 化学治療における市場規模
- 標的治療における市場規模
- 免疫治療における市場規模
・世界の非小細胞性肺がん市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の非小細胞性肺がん市場規模：地域別
- 北米の非小細胞性肺がん市場規模
- ヨーロッパの非小細胞性肺がん市場規模
- アジア太平洋の非小細胞性肺がん市場規模
- 中南米・中東・アフリカの非小細胞性肺がん市場規模
・企業状況
・企業情報

世界の非小細胞性肺がん市場は、2021年に153億3,500万ドル、2031年には369億3,419万ドルに達すると予測され、2022年から2031年までのCAGRは9.3%となる見込みです。

非小細胞性肺がん（NSCLC）は、肺の上皮組織に発生する肺がんの一種です。NSCLCは主に喫煙者または喫煙歴のある人に発症します。また、ラドンやアスベストなどの汚染された空気にさらされている人にも発生します。患者さんのがんの治療には、免疫療法、分子標的治療、化学療法など、さまざまな手法を用いる必要があります。
NSCLCは、特に病気が他の臓器に広がる前に手を打てば治ります。がんが肺のごく狭い範囲にとどまっている場合は、医師による手術が必要な場合もあります。より進行した悪性腫瘍の場合は、追加の治療が必要になることもあります。さらに、タバコの消費量の増加、非小細胞性肺がんの有病率の上昇、がんの早期検診、抗がん剤の入手可能性などが、市場の成長を後押しすると予想されています。例えば、国立生物工学情報センター（NCBI）によると、肺がん疾患の85％は非小細胞性肺がん症例です。

しかし、抗がん剤治療に関連する副作用の脅威と相まって、治療療法に伴う高コストが市場の成長を抑制すると予想されます。逆に、新興経済圏の潜在力の高さとパイプラインにある潜在的な薬剤の数の多さは、将来的に市場プレーヤーに新たな機会を提供すると期待されています。

世界のNSCLC治療市場は、種類別、治療タイプ別、流通チャネル別、地域別に区分されます。治療タイプにより、市場は化学療法、標的療法、免疫療法に分類されます。種類別では、腺がん、扁平上皮がん、大細胞がん、その他（腺扁平上皮がん、肉腫様がん）に分類され、流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンライン薬局に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋（中国、日本、オーストラリア、インド、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、LAMEAのその他地域）に市場を分けて分析しています。

本レポートに掲載されている主要企業には、AstraZeneca PLC、Bristol-Myers Squibb Company、Eli Lilly、F. Hoffmann-La Roche Ltd.、Johnson & Johnson (Janssen Global Services, LLC)、Merck & Co., Inc.、Novartis AG、Pfizer Inc.、Sanofi SA、Teva Pharmaceuticals Industries Ltd.などがあります。

〈ステークホルダーにとっての主なメリット〉
・2021年から2031年にかけての世界の非小細胞性肺がん市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、世界の非小細胞性肺がん市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・世界の非小細胞性肺がん市場の細分化に関する詳細な分析により、市場機会を特定します。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界の非小細胞性肺がん市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
扁平上皮がん
大細胞がん
腺がん
その他

治療タイプ別
化学療法
標的療法
免疫療法

販売チャネル別
病院薬局
ドラッグストア・小売薬局
オンライン薬局

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
Astrazeneca
Eli Lilly and Company
Merck & Co., Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Sanofi
boehringer ingelheim

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Adenocarcinoma
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Squamous Cell Carcinoma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Large Cell Carcinoma
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
CHAPTER 5: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Chemotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Targeted Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Immunotherapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
CHAPTER 6: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug Store and Retail Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment Type
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Treatment Type
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Treatment Type
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Treatment Type
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment Type
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Treatment Type
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Treatment Type
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Treatment Type
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Treatment Type
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Treatment Type
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Treatment Type
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Treatment Type
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Treatment Type
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Treatment Type
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Treatment Type
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Treatment Type
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Treatment Type
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment Type
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Treatment Type
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Treatment Type
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Treatment Type
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Treatment Type
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 F. Hoffmann-La Roche Ltd
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Novartis AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Astrazeneca
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Bristol-Myers Squibb Company
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Celgene Corporation
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 boehringer ingelheim
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ADENOCARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR LARGE CELL CARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR LARGE CELL CARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 18. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 26. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 30. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 34. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 36. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 59. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 86. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 95. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 96. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 98.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 99.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 100.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 101.F. HOFFMANN-LA ROCHE LTD: NET SALES
TABLE 102.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 104.NOVARTIS AG: OPERATING SEGMENTS
TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 106.NOVARTIS AG: NET SALES
TABLE 107.NOVARTIS AG: KEY STRATERGIES
TABLE 108.PFIZER INC.: COMPANY SNAPSHOT
TABLE 109.PFIZER INC.: OPERATING SEGMENTS
TABLE 110.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 111.PFIZER INC.: NET SALES
TABLE 112.PFIZER INC.: KEY STRATERGIES
TABLE 113.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 114.ASTRAZENECA: OPERATING SEGMENTS
TABLE 115.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 116.ASTRAZENECA: NET SALES
TABLE 117.ASTRAZENECA: KEY STRATERGIES
TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 121.ELI LILLY AND COMPANY: NET SALES
TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 123.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 124.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 125.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 126.MERCK & CO., INC.: NET SALES
TABLE 127.MERCK & CO., INC.: KEY STRATERGIES
TABLE 128.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 129.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 130.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 131.BRISTOL-MYERS SQUIBB COMPANY: NET SALES
TABLE 132.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 133.CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 134.CELGENE CORPORATION: OPERATING SEGMENTS
TABLE 135.CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 136.CELGENE CORPORATION: NET SALES
TABLE 137.CELGENE CORPORATION: KEY STRATERGIES
TABLE 138.SANOFI: COMPANY SNAPSHOT
TABLE 139.SANOFI: OPERATING SEGMENTS
TABLE 140.SANOFI: PRODUCT PORTFOLIO
TABLE 141.SANOFI: NET SALES
TABLE 142.SANOFI: KEY STRATERGIES
TABLE 143.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 144.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 145.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 146.BOEHRINGER INGELHEIM: NET SALES
TABLE 147.BOEHRINGER INGELHEIM: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 非小細胞性肺がんのグローバル市場（2023～2030）
  • 扁平上皮癌（SCC）抗原定量キットのグローバル市場予測2023-2029
  • 色素異常症治療のグローバル市場（2021〜2031）：白斑、肝斑、その他
  • コンパニオンアニマル関節炎のグローバル市場（2021～2031）：犬、猫、馬
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB253 )"非小細胞性肺がんのグローバル市場（2021〜2031）：腺癌、扁平上皮癌、大細胞癌、その他" (英文：Global Non Small-Cell Lung Cancer Market By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。